Japan's Takeda has secured its first regulatory approval – in Indonesia – for its dengue fever vaccine TAK-003, which has been tipped as a potential blockbuster product.

Takeda has unexpectedly withdrawn its marketing application with the FDA for dengue fever vaccine TAK-003 and said it will reconsider whether it will attempt to bring it to market in the US.

HYDERABAD: Japanese pharma giant Takeda has entered into a strategic partnership with Hyderabad-based biopharma player Biological E Limited (BE), to manufacture up to 50 million doses of Takeda ...

HYDERABAD: Takeda and Biological E Limited (BE), a leading India-based Vaccines and Pharmaceutical Company, on Tuesday, announced a strategic partnership to accelerate access to QDENGA (Dengue ...

In a large trial, a dengue immunization developed by Takeda Vaccines reduced the number of dengue by more than 80 percent relative to a control group, and cut the number of hospitalizations due to the ...

The development of dengue vaccine has been a focus of utmost importance ... attenuated vaccine based on DENV2-PDK-53 CDC/Inviragen/Takeda Phase II Live-attenuated vaccine based on DEN4Δ30 ...

approved the use in the country of a vaccine against dengue developed by the Japanese laboratory Takeda. The regulatory agency approved the drug for people aged 4 and over, regardless of whether ...

India experiences the world’s absolute burden of at least 11 NTDs, including hookworm, dengue, lymphatic filariasis, leprosy, ...

Why is there still no dengue vaccine in the country?” This was the question posed by Union of Local Authorities of the Philippines president and Quirino governor Dax Cua to the Department of Health, a ...

The drug, produced by the laboratory Takeda, targets “dengue virus ... Salta will be the first province in the country to apply the vaccine against dengue. The provincial government will buy ...